{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:08:49Z","timestamp":1793239729720,"version":"4.5.0"},"reference-count":53,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"unspecified","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NIH","award":["1R01HL170627-01"],"award-info":[{"award-number":["1R01HL170627-01"]}]},{"name":"NIH","award":["T32HP19025"],"award-info":[{"award-number":["T32HP19025"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,30]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate and map research examining clinical associations with the Duffy-null variant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Scoping review of the existing literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>We conducted a systematic search of PubMed, Embase, CINAHL and Web of Science for studies published in English between 1 January 2000 and 25 June 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility<\/jats:title>\n                    <jats:p>Studies were eligible for inclusion if they examined associations relevant to current standard clinical practice and met our protocol\u2019s inclusion criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction<\/jats:title>\n                    <jats:p>We extracted the following information from included studies: study year(s), patient population, sample size, study design, primary outcome and primary findings. Studies were grouped by outcome and synthesised in tabular and qualitative formats.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 2737 studies were screened, and 44 met our inclusion criteria. Most studies were observational, and the most common research question examined was the association with resistance to\n                      <jats:italic>Plasmodium vivax<\/jats:italic>\n                      malaria (9\/44). Overall, we observed that the association between the Duffy-null variant and asymptomatic lower absolute neutrophil count (ANC) is demonstrated in large prospective cohort studies. The association with resistance to\n                      <jats:italic>P. vivax<\/jats:italic>\n                      malaria is primarily supported by large cross-sectional studies. There were no studies examining the practical applications of these findings, for example, optimal Duffy-genotype adjusted ANC thresholds for clinical decision-making in patients receiving chemotherapy. Finally, we observed that 19 different associations with this trait have been explored, several in conditions with no clear link to the Duffy trait, for example, progression rates in HIV\/AIDS, risk of diabetes, etc.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      We found established associations between the Duffy-null variant and asymptomatic lower ANC and with resistance to\n                      <jats:italic>P. vivax<\/jats:italic>\n                      malaria but a lack of data for the practical utilisation of these findings in clinical care. Future studies, such as those examining safe ANC values for entry into clinical trials and for ANC nadir for Duffy-null patients receiving medications associated with increased risk of neutropenia, for example, clozapine, are needed. We observed numerous reported associations of unclear clinical utility. Studies investigating associations with the Duffy trait should be guided by biologic plausibility and clinical utility of positive findings.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-099049","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:51:12Z","timestamp":1763628672000},"page":"e099049","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Duffy-null variant and practical implications for patient care: a scoping review"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7617-0677","authenticated-orcid":false,"given":"Edgar","family":"Asiimwe","sequence":"first","affiliation":[{"name":"National Clinician Scholars Program, UCSF, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thye Peng","family":"Ngo","sequence":"additional","affiliation":[{"name":"National Clinician Scholars Program, UCSF, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Ziv","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine at Mt. Zion, UCSF, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D","family":"Leavitt","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, UCSF, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"2025112000502853000_15.11.e099049.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2007.09.003"},{"key":"2025112000502853000_15.11.e099049.2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000360","article-title":"Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene","volume":"5","author":"Reich","year":"2009","journal-title":"PLoS Genet"},{"key":"2025112000502853000_15.11.e099049.3","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3763"},{"key":"2025112000502853000_15.11.e099049.4","unstructured":"1-159204893-t-c | gnomAD v4.1.0. gnomAD. 2025 Available: https:\/\/gnomad.broadinstitute.org\/variant\/1-159204893-T-C?dataset=gnomad_r4"},{"key":"2025112000502853000_15.11.e099049.5","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms1265","article-title":"The global distribution of the Duffy blood group","volume":"2","author":"Howes","year":"2011","journal-title":"Nat Commun"},{"key":"2025112000502853000_15.11.e099049.6","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850"},{"key":"2025112000502853000_15.11.e099049.7","unstructured":"10.2 development of a scoping review protocol. JBI Manual for Evidence Synthesis - JBI Global. 2025 Available: https:\/\/jbi-global-wiki.refined.site\/space\/MANUAL\/355862619\/10.2+Development+of+a+scoping+review+protocol"},{"key":"2025112000502853000_15.11.e099049.8","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e318219c171"},{"key":"2025112000502853000_15.11.e099049.9","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0596-4"},{"key":"2025112000502853000_15.11.e099049.10","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-018-2588-7"},{"key":"2025112000502853000_15.11.e099049.11","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-13-170","article-title":"Molecular typing reveals substantial Plasmodium vivax infection in asymptomatic adults in a rural area of Cameroon","volume":"13","author":"Fru-Cho","year":"2014","journal-title":"Malar J"},{"key":"2025112000502853000_15.11.e099049.12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103262","article-title":"Molecular evidence of Plasmodium vivax mono and mixed malaria parasite infections in Duffy-negative native Cameroonians","volume":"9","author":"Ngassa Mbenda","year":"2014","journal-title":"PLoS One"},{"key":"2025112000502853000_15.11.e099049.13","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-024-04895-1","article-title":"Epidemiology of Plasmodium vivax in Duffy negatives and Duffy positives from community and health centre collections in Ethiopia","volume":"23","author":"Bradley","year":"2024","journal-title":"Malar J"},{"key":"2025112000502853000_15.11.e099049.14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.4269\/ajtmh.18-0417","article-title":"Risk Factors for Malaria Infection in Central Madagascar: Insights from a Cross-Sectional Population Survey","volume":"99","author":"Howes","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"2025112000502853000_15.11.e099049.15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-32254-z","article-title":"Susceptibility to Plasmodium vivax malaria associated with DARC (Duffy antigen) polymorphisms is influenced by the time of exposure to malaria","volume":"8","author":"Kano","year":"2018","journal-title":"Sci Rep"},{"key":"2025112000502853000_15.11.e099049.16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011326","article-title":"Potential hidden Plasmodium vivax malaria reservoirs from low parasitemia Duffy-negative Ethiopians: Molecular evidence","volume":"17","author":"Abebe","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"key":"2025112000502853000_15.11.e099049.17","doi-asserted-by":"crossref","DOI":"10.3390\/genes10060437","article-title":"Distribution of Duffy Phenotypes among Plasmodium vivax Infections in Sudan","volume":"10","author":"Albsheer","year":"2019","journal-title":"Genes (Basel)"},{"key":"2025112000502853000_15.11.e099049.18","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1001\/jama.2023.7467","article-title":"Development of Duffy Null-Specific Absolute Neutrophil Count Reference Ranges","volume":"329","author":"Merz","year":"2023","journal-title":"JAMA"},{"key":"2025112000502853000_15.11.e099049.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07335.x"},{"key":"2025112000502853000_15.11.e099049.20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/bloodadvances.2023010400","article-title":"Clinical and immunological features in ACKR1\/DARC-associated neutropenia","volume":"8","author":"Palmblad","year":"2024","journal-title":"Blood Adv"},{"key":"2025112000502853000_15.11.e099049.21","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1093\/hmg\/ddaa208","article-title":"The Duffy-null genotype and risk of infection","volume":"29","author":"Legge","year":"2020","journal-title":"Hum Mol Genet"},{"key":"2025112000502853000_15.11.e099049.22","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1001\/jamainternmed.2021.3108","article-title":"Association Between a Common, Benign Genotype and Unnecessary Bone Marrow Biopsies Among African American Patients","volume":"181","author":"Van Driest","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2025112000502853000_15.11.e099049.23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ejh.13963","article-title":"Clinical outcomes of patients referred for asymptomatic neutropenia: A focus on racial disparities in hematology","volume":"111","author":"Oyogoa","year":"2023","journal-title":"Eur J Haematol"},{"key":"2025112000502853000_15.11.e099049.24","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1002\/cncr.33620","article-title":"Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer","volume":"127","author":"Lynce","year":"2021","journal-title":"Cancer"},{"key":"2025112000502853000_15.11.e099049.25","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.7326\/M21-4675","article-title":"Race, Genotype, and Azathioprine Discontinuation: A Cohort Study","volume":"175","author":"Dickson","year":"2022","journal-title":"Ann Intern Med"},{"key":"2025112000502853000_15.11.e099049.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0335-7"},{"key":"2025112000502853000_15.11.e099049.27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.schres.2023.08.002","article-title":"Clozapine and neutrophil response in patients of African descent: A six-month, multinational, prospective, open-label clinical trial","volume":"268","author":"Kelly","year":"2024","journal-title":"Schizophr Res"},{"key":"2025112000502853000_15.11.e099049.28","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir119"},{"key":"2025112000502853000_15.11.e099049.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-215186"},{"key":"2025112000502853000_15.11.e099049.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2008.06.002"},{"key":"2025112000502853000_15.11.e099049.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2009.04.011"},{"key":"2025112000502853000_15.11.e099049.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2009.04.013"},{"key":"2025112000502853000_15.11.e099049.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2009.04.010"},{"key":"2025112000502853000_15.11.e099049.34","doi-asserted-by":"publisher","DOI":"10.1002\/aorn.12722"},{"key":"2025112000502853000_15.11.e099049.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01622.x"},{"key":"2025112000502853000_15.11.e099049.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2010.02.023"},{"key":"2025112000502853000_15.11.e099049.37","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.089243"},{"key":"2025112000502853000_15.11.e099049.38","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1523-1755.2004.00871.x","article-title":"Duffy antigen receptor and genetic susceptibility of African Americans to acute rejection and delayed function","volume":"66","author":"Mange","year":"2004","journal-title":"Kidney Int"},{"key":"2025112000502853000_15.11.e099049.39","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000061228.38243.26"},{"key":"2025112000502853000_15.11.e099049.40","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-12-374","article-title":"Correlation between Duffy blood group phenotype and breast cancer incidence","volume":"12","author":"Liu","year":"2012","journal-title":"BMC Cancer"},{"key":"2025112000502853000_15.11.e099049.41","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000790","article-title":"Ancestry, ACKR1 and leucopenia in patients with systemic lupus erythematosus","volume":"9","author":"Chung","year":"2022","journal-title":"Lupus Sci Med"},{"key":"2025112000502853000_15.11.e099049.42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.htct.2022.01.002","article-title":"Association between FY*02N.01 and the severity of COVID-19: initial observations","volume":"44","author":"Conrado","year":"2022","journal-title":"Hematol Transfus Cell Ther"},{"key":"2025112000502853000_15.11.e099049.43","first-page":"S208","article-title":"A genetic clue to disparities in outcome of acute lung injury","volume":"25","author":"Kangelaris","year":"2010","journal-title":"J Gen Intern Med"},{"key":"2025112000502853000_15.11.e099049.44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4269\/ajtmh.2005.73.44","article-title":"Antibody response to Plasmodium vivax antigens in Fy-negative individuals from the Colombian Pacific coast","volume":"73","author":"Herrera","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"2025112000502853000_15.11.e099049.45","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-88613-w","article-title":"Investigation of triple-negative breast cancer risk alleles in an International African-enriched cohort","volume":"11","author":"Martini","year":"2021","journal-title":"Sci Rep"},{"key":"2025112000502853000_15.11.e099049.46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2002.01181.x"},{"key":"2025112000502853000_15.11.e099049.47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083286","article-title":"Association of duffy blood group gene polymorphisms with IL8 gene in chronic periodontitis","volume":"8","author":"Sippert","year":"2013","journal-title":"PLoS One"},{"key":"2025112000502853000_15.11.e099049.48","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104430","article-title":"Duffy blood group system and ocular toxoplasmosis","volume":"85","author":"Ferreira","year":"2020","journal-title":"Infect Genet Evol"},{"key":"2025112000502853000_15.11.e099049.49","first-page":"822","article-title":"Hypertension, type 2 diabetes, and blood groups in a population of African ancestry","volume":"16","author":"Nemesure","year":"2006","journal-title":"Ethn Dis"},{"key":"2025112000502853000_15.11.e099049.50","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.4254\/wjh.v7.i10.1433","article-title":"Genetic ancestry analysis in non-alcoholic fatty liver disease patients from Brazil and Portugal","volume":"7","author":"Cavalcante","year":"2015","journal-title":"WJH"},{"key":"2025112000502853000_15.11.e099049.51","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/dna.2011.1321","article-title":"Do FY antigens act as minor histocompatibility antigens in the graft-versus-host disease paradigm after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation?","volume":"31","author":"Sellami","year":"2012","journal-title":"DNA Cell Biol"},{"key":"2025112000502853000_15.11.e099049.52","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jamacardio.2018.1042","article-title":"Association of Neutrophil-to-Lymphocyte Ratio With Mortality and Cardiovascular Disease in the Jackson Heart Study and Modification by the Duffy Antigen Variant","volume":"3","author":"Kim","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2025112000502853000_15.11.e099049.53","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102824","article-title":"Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward","volume":"76","author":"Mittal","year":"2024","journal-title":"EClinicalMedicine"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-099049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:51:18Z","timestamp":1763628678000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-099049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":53,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,19]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjopen-2025-099049"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-099049","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}